Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis
© The Author(s). 2016
Received: 6 August 2016
Accepted: 17 November 2016
Published: 23 December 2016
Acute retinal necrosis is a rare but devastating ocular condition. We report two cases of acute retinal necrosis in immunocompetent patients, complicated by cystoid macular oedema and treated with intravitreal dexamethasone (OZURDEX®) implant.
Two patients diagnosed with acute retinal necrosis were treated with intravenous acyclovir. Both of them developed cystoid macular oedema following resolution of viral retinitis. Ocular condition of the first patient was further complicated by central serous chorioretinopathy. Under unavoidable circumstances, cystoid macular oedema in both the patients was treated with intravitreal dexamethasone implant with great caution. Resolution of cystoid macular oedema without recurrence of viral retinitis was noted in the long-term follow-up.
Findings of the case report should be interpreted cautiously, and extreme caution should be exercised prior deciding the management with a corticosteroid implant in patients with viral retinitis. However, intravitreal dexamethasone implant can be a useful option in selected patients with cystoid macular oedema in acute retinal necrosis.
KeywordsAcute retinal necrosis Cystoid macular oedema
Acute retinal necrosis (ARN) is an uncommon, devastating, and potentially blinding necrotizing retinitis. It is most commonly seen in healthy young individuals, but can be seen in immunocompromised patients also . ARN is a clinical diagnosis, and polymerase chain reaction of the vitreous or aqueous aspirate can be used to identify the viral DNA responsible for the disease . The major causes of poor visual outcome in a case of ARN are retinal detachment, optic nerve, or macular involvement by ischemic vasculopathy . Involvement of the posterior pole is relatively uncommon, except for inflammatory macular oedema, epimacular membrane formation, or retinitis in untreated or late stages of the disease. Cystoid macular oedema in these patients tends to be recurrent and resistant to treatment, threatening central vision even after resolution of ocular inflammation and requires additional treatment .
We report two cases of ARN in immunocompetent patients, complicated by cystoid macular oedema and treated with intravitreal dexamethasone (OZURDEX®) implant.
A 36-year-old, otherwise healthy woman presented to us with sudden painless reduction of vision in her left eye since 1 month. She was diagnosed with ARN elsewhere 20 days back and was on oral valacyclovir 1 g twice a day and oral steroid 20 mg/day.
The patient was started on intravenous acyclovir 500 mg three times a day. Subsequently, she was started on oral corticosteroid 40 mg/day. After 3 weeks of intravenous therapy, oral valacyclovir 1 g three times was started with tapering of oral steroids. Within 3 weeks, with resolving vitritis and retinitis, her BCVA improved to 6/7.5, N10. Prophylactic laser treatment was applied on the normal retina to surround the posterior edge of the necrotic retina by rows of confluent and circumferential laser burns (Fig. 1b).
Her condition remained stable for 3 months when she came back with a drop in vision, and her BCVA in left eye was 6/9, N10. Fundus examination revealed cystoid macular oedema (CME) in the left eye, which was confirmed in optical coherence tomography (OCT) with thickness of 422 μ. She was started on topical nepafenac, and dose of oral steroid was hiked up to 50 mg/day.
She came back after a month with sudden drop in vision in her left eye. Her BCVA in the left eye was 6/36, N12. Fundus examination of the left eye revealed pocket of subretinal fluid in the inferotemporal quadrant. Fluorescein angiography (FFA) confirmed the presence of central serous chorioretinopathy (CSR) (Fig. 1c). Optical coherence tomography (OCT) confirmed the presence of CSR with deterioration of CME in the left eye with thickness of 573 μ (figure). She was advised to stop oral steroid, and focal laser to the leak was done. She came back after a month with resolved CSR and persistent CME, and her BCVA improved to 6/12, N9 in the left eye.
After 4 months, he returned to the clinic reporting further decrease of vision in the previously affected eye. His BCVA in the left eye was 6/36. Fundus examination revealed some vitreous floaters and a blunted foveal reflex. No reactivation of retinitis was noted. SD-OCT revealed the formation of cystoid macular oedema with retinal thickness measuring 508 μ (Fig. 3b). The patient was commenced on oral valacyclovir 1 g tid, and advised for pars plana vitrectomy. After 3 weeks, there was a remarkable resolution of CME, and BCVA improved to 6/12. Treatment was tapered to 1 g valacyclovir, and retinitis remained quiescent over follow-up.
Two months later, patient returned with a drop in vision in the left eye. His BCVA was 6/24, N12 and SD-OCT revealed deterioration of CME with retinal thickness of 465 μ (Fig. 3c). Anti-VEGF injection was given with no improvement in BCVA or OCT 1 month later. Since he had declined all systemic forms of therapy, the patient was counselled to administer an Ozurdex injection. Valacyclovir was increased to 1 g three times day. One month after injection, his BCVA improved to 6/9 and retinal thickness reduced to 265 μ with complete resolution of CME (Fig. 3d). She was continued oral antiviral for 6 months following intravitreal injection of Ozurdex.
Three months later, she came back with a drop in BCVA and fundus examination revealed recurrence of CME in the left eye. She was treated with a repeat Ozurdex injection which resulted in resolution of CME with BCVA of 6/12 in 6 weeks.
ARN is a severe necrotizing vasoocclusive retinitis caused by herpes viruses. In the absence of appropriate treatment, retinitis progresses circumferentially with subsequent devastating visual outcome. Posterior pole involvement with retinitis is uncommon and includes the development of macular oedema, epimacular membranes, macular holes, and macular ischemia.
Although signs of intraocular inflammation disappear usually between 6 and 12 weeks following the onset of treatment, post ARN macular oedema can pose a chronic recurrent problem and a therapeutic challenge, with possible consequent reduction of central vision. CSR in ARN is very rare, but has been reported in literature .
The role of systemic corticosteroid therapy in controlling intraocular inflammation and resolution of the vitritis in ARN is generally well accepted . Literature on use of intravitreal corticosteroid in ARN is sparse. In fact, local administration of corticosteroid has been implicated to reactivate viral retinitis [6–8]. However, in many of the cases reported, there were associated comorbidities and many of these patients were on immunosuppression for a long time . Thus, definitive proof for potential risk of developing necrotizing retinitis following periocular or intraocular corticosteroids is yet to be ascertained.
Management of cystoid macular oedema following viral uveitis is always challenging and frustrating. There is no standard treatment regimen for uveitic macular oedema. Various available treatment modalities for uveitic macular oedema include topical, regional and systemic corticosteroids, immunosuppressive, and VEGF inhibitors. VEGF inhibitors have been tried in uveitic macular oedema with variable results [9–11]. The role of intravitreal corticosteroid in cystoid macular oedema has been well-established. However, the use of intravitreal steroid in infectious retinitis remains questionable and should not be advocated as primary treatment modality. Intravitreal triamcinolone (IVTA) in adjuvant with intravitreal foscarnet has been used to treat optic nerve oedema in a patient with acute retinal necrosis . Choudhury et al.  treated four eyes of ARN with IVTA under oral antiviral cover in absence of new active lesions.
Our cases illustrate the clinical efficacy of Ozurdex in the treatment of CME in patients with ARN. However, extreme caution should be exercised prior deciding the management with a corticosteroid implant in patients with viral retinitis. In the absence of active necrotizing retinitis and long-term treatment with antiviral agents, Ozurdex can be a useful tool for the management of CME associated with ARN.
JB, PDM, and RA saw the patients and collected the data from the medical history. ZR and AA prepared the outline and figures for the manuscript. PDM and RA have prepared the manuscript. All the authors read and approved the final manuscript.
The authors declare that they have no competing interests. This paper has never been submitted to any journal nor published in any form of media before.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Bonfioli AA, Eller AW (2005) Acute retinal necrosis. Semin Ophthalmol 20(3):155–160. doi:10.1080/08820530500232027 View ArticlePubMedGoogle Scholar
- Almeida DR, Chin EK, Tarantola RM et al (2015) Long-term outcomes in patients undergoing vitrectomy for retinal detachment due to viral retinitis. Clin Ophthalmol Auckl NZ 9:1307–1314. doi:10.2147/OPTH.S87644 Google Scholar
- Aizman A (2006) Treatment of acute retinal necrosis syndrome. Drugs Today Barc Spain 1998 42(8):545–551. doi:10.1358/dot.2006.42.8.1021519 Google Scholar
- Stuebiger N, Biester S, Deuter CME, Zierhut M (2008) An unusual case of central serous chorioretinopathy in a patient with acute retinal necrosis. Ocul Immunol Inflamm 16(3):109–111. doi:10.1080/09273940802056299 View ArticlePubMedGoogle Scholar
- Wong RW, Jumper JM, McDonald HR et al (2013) Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol 97(5):545–552. doi:10.1136/bjophthalmol-2012-301983 View ArticlePubMedGoogle Scholar
- Takakura A, Tessler HH, Goldstein DA et al (2014) Viral retinitis following intraocular or periocular corticosteroid administration: a case series and comprehensive review of the literature. Ocul Immunol Inflamm 22(3):175–182. doi:10.3109/09273948.2013.866256 View ArticlePubMedPubMed CentralGoogle Scholar
- Shah AM, Oster SF, Freeman WR (2010) Viral retinitis after intravitreal triamcinolone injection in patients with predisposing medical comorbidities. Am J Ophthalmol 149(3):433–440. doi:10.1016/j.ajo.2009.10.019, e1View ArticlePubMedPubMed CentralGoogle Scholar
- Ramaiya KJ, Rao PK (2011) Herpetic necrotizing retinitis following flucinolone acetonide intravitreal implant. Ocul Immunol Inflamm 19(1):72–74. doi:10.3109/09273948.2010.520404 View ArticlePubMedGoogle Scholar
- Ziemssen F, Deuter CM, Stuebiger N, Zierhut M (2007) Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin). Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Für Klin Exp Ophthalmol 245(6):917–918. doi:10.1007/s00417-006-0512-2 View ArticleGoogle Scholar
- Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS (2007) Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114(8):1574–1579. doi:10.1016/j.ophtha.2006.11.028, e1View ArticlePubMedGoogle Scholar
- Mackensen F, Heinz C, Becker MD, Heiligenhaus A (2008) Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina Phila Pa 28(1):41–45. doi:10.1097/IAE.0b013e318156db75 View ArticleGoogle Scholar
- Munson PD, Nelson ML, Crawford C, Rivers BA, Young PE (2015) Use of intravitreal triamcinolone for the treatment of optic nerve edema in a patient with acute retinal necrosis: case report. Retin Cases Brief Rep 9(2):102–103. doi:10.1097/ICB.0000000000000100 View ArticlePubMedGoogle Scholar
- Choudhury H, Jindal A, Mithal K, Bawdekar AC, Pathengay A (2014) Intravitreal triamcinolone acetonide as an adjuvant in the management of acute retinal necrosis. Can J Ophthalmol J Can Ophtalmol 49(3):279–282. doi:10.1016/j.jcjo.2014.03.010 View ArticleGoogle Scholar